Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Alzheimer's Clinical Trials: First Patient Dosed with Leronlimab
Alzheimer's Clinical Trials: First Patient Dosed with Leronlimab
Read also
FDA Expands Approval of Sanofi's Tzield for Type 1 Diabetes in Kids
Sanofi's Tzield receives an expanded FDA drug approval for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes.
Prader-Willi Syndrome Treatment: Setmelanotide Phase 2 Results
Rhythm Pharmaceuticals reports a significant 7-point hyperphagia reduction in its Phase 2 trial of setmelanotide for Prader-Willi syndrome.
FDA Grants Fast Track Designation for Novel Sepsis Treatment Isupartob
Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium, accelerating the clinical trials and development of a novel sepsis treatment.
Symeres Expands Spray Drying Capabilities for Complex Drug Formulation
Symeres enhances its CMC site in New Jersey with expanded spray drying capabilities, optimizing drug formulation development for poorly soluble candidates.
